Cellvizio by Mauna Kea Technologies

Cellvizio by Mauna Kea Technologies Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

11/20/2025

Today we announce that we have obtained approval from the National Medical Products Administration (NMPA) in China for the import and commercialization of Cellvizio, which authorizes the use in China of the Gen 3 platform in conjunction with our full range of confocal probes.

China's interventional endoscopy market shows strong demand for precision diagnostic technologies, and we're now evaluating commercialization options to bring this cutting-edge platform to Chinese hospitals, practitioners, and patients. This approval reinforces our commitment to expanding access to innovative medical technology worldwide.

Read the full PR: https://hubs.la/Q03Vj5Vb0

The publication “Diagnosis and Management of Pancreatic Cysts: A Comprehensive Review of the Literature”, delves into th...
11/20/2025

The publication “Diagnosis and Management of Pancreatic Cysts: A Comprehensive Review of the Literature”, delves into the value of adding novel techniques, such as nCLE, with endoscopic ultrasound (EUS).
(Singh R, et al., 2023.)

Read the full publication: https://hubs.la/Q03VdF_r0

Cellvizio nCLE is transforming pancreatic cyst management in clinical practice: https://hubs.la/Q03Vds6S0

The publication “Role of Endoscopic Ultrasound in the Evaluation of Pancreatic Cystic Neoplasms: A Concise Review” summa...
11/18/2025

The publication “Role of Endoscopic Ultrasound in the Evaluation of Pancreatic Cystic Neoplasms: A Concise Review” summarizes the specific role of endoscopic ultrasound (EUS) in the management of pancreatic cysts, finding that though "EUS morphology is utilized for standard of care evaluation of pancreatic cysts, [...] adjunctive imaging technologies, such as EUS-nCLE and [contrast-harmonic mode] CH-EUS, can be utilized to improve management." (Rangwani S, et al., 2023.)

Read the full publication: https://hubs.la/Q03TB1rV0
Explore Cellvizio's clinical applications for pancreatic cysts: https://hubs.la/Q03TB53K0

We are pleased to announce the achievement of major financial milestones, securing a robust foundation for our future. W...
11/14/2025

We are pleased to announce the achievement of major financial milestones, securing a robust foundation for our future. We have successfully finalized a significant financial restructuring which provides long-term visibility, with 90% of the remaining debt scheduled for repayment between the end of 2029 and the end of 2035. With a strengthened financial position, our focus is now fully directed toward executing our growth strategy and achieving sustainable profitability.

We thank our partners, lenders and investors for their confidence and support as we enter this new chapter.

For complete details, you can read the full press release here: https://hubs.ly/Q03TkWfL0

11/12/2025

Lung cancer is the world’s leading cause of cancer deaths, and its diagnosis remains challenging. Our mission at Mauna Kea Technologies is to empower physicians to achieve an earlier, more definitive diagnosis.

To learn how Cellvizio advanced imaging improves diagnostic accuracy, visit: https://hubs.la/Q03SNtlH0

While not all pancreatic cysts are cancerous, some are, and some can undergo changes over time that increase the risk fo...
11/06/2025

While not all pancreatic cysts are cancerous, some are, and some can undergo changes over time that increase the risk for pancreatic cancer. Cellvizio® is the real-time in vivo cellular imaging platform that significantly improves the classification of indeterminate cysts quickly and with more certainty.

See how CLE advanced imaging can refine your diagnostic approach and treatment strategies: https://hubs.la/Q03RysKg0


Pancreatic Cancer Action Network

11/05/2025

Join our on-site workshop with live cases to gain the latest insights into , led by nCLE expert Bertrand Napoleon, MD at Ramsay Santé on December 3rd.

To attend this Live Cases event, sign up here:
https://hubs.ly/Q03RQ4j40

10/30/2025

Dr. Somashekar Krishna and his team published landmark research in Pancreatology, demonstrating that combined with AI significantly outperforms human experts in risk stratification of pancreatic cysts (IPMNs). Combined with validated CLIMB study data from Digestive Disease Week® (DDW®), the evidence is clear: Cellvizio delivers unmatched accuracy in pancreatic cyst diagnosis. We're driving the future of precision medicine to improve patient outcomes.

Learn more about this breakthrough: https://hubs.la/Q03QWKf50

Elsevier

The Pancreatic Cyst Consortium continues to bring together leading minds in gastroenterology. With 75 physicians partici...
10/28/2025

The Pancreatic Cyst Consortium continues to bring together leading minds in gastroenterology. With 75 physicians participating in our latest session, the collaborative momentum around pancreatic cyst research and management is stronger than ever. When experts unite, breakthroughs happen.

Ready to enhance your pancreatic cyst evaluations? https://hubs.la/Q03QhHrF0

Making the hidden food triggers behind patient symptoms finally visible. At Stanford Health Care, Dr. Sean Spencer is us...
10/24/2025

Making the hidden food triggers behind patient symptoms finally visible. At Stanford Health Care, Dr. Sean Spencer is using , powered by Cellvizio by Mauna Kea Technologies, to explore how specific foods can irritate the gut lining, offering new clarity for patients with unexplained digestive issues. By visualizing what’s happening inside the intestine in real time, this approach moves beyond guesswork and helps patients find truly personalized relief.

🔗 Read the full story: https://hubs.la/Q03Q3WMN0

10/23/2025

Cellvizio is officially recommended in the latest European Society of Gastrointestinal Endoscopy (ESGE) guidelines for the characterization of pancreatic cystic lesions. This is a major step towards improving diagnostic accuracy and reducing unnecessary surgeries for patients worldwide.

🔬Why adding Cellvizio matters:
✔️Improves diagnostic accuracy to 97-98%
✔️Reduces unnecessary surgeries by 23%
✔️>50% of pancreatic cysts remain inconclusive after fine-needle aspiration (EUS-FNA)

Read more: https://hubs.ly/Q03PTTJK0

Mauna Kea Technologies reports +16% total revenue growth (Constant Exchange Rates), driven by a 31% surge in U.S. sales ...
10/15/2025

Mauna Kea Technologies reports +16% total revenue growth (Constant Exchange Rates), driven by a 31% surge in U.S. sales (CER) with system sales doubling year to date. Business activity grew by +18% (CER), primarily driven by the international expansion of the application for food intolerances and our continued success with is fueled by excellent clinical data and strong physician support. We are opening a new chapter of growth!

Read the full PR: https://hubs.la/Q03NMN2J0

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.